Table 4.
Analysis of prognostic factors in 512 patients with gastric cancer with an SRC component.
| Variables | Survival analysis | |
|---|---|---|
| 5-YSR (%) | p value | |
| Sex | ||
| Male | 53.3 | 0.639 |
| Female | 51.7 | |
| Age (years) | ||
| <55 | 58.5 | 0.007 |
| ≥55 | 47.4 | |
| Tumor size (cm) | ||
| <4.75 | 72.8 | <0.001 |
| ≥4.75 | 36.6 | |
| Chemotherapy | ||
| Yes | 56.6 | 0.059 |
| No | 49.3 | |
| SRCC | ||
| mSRCC | 53.6 | 0.432 |
| pSRCC | 47.1 | |
| T-stage | ||
| T1 | 97.6 | <0.001 |
| T2 | 82.8 | |
| T3 | 50.0 | |
| T4 | 34.4 | |
| N-stage | ||
| N0 | 83.1 | <0.001 |
| N1 | 55.8 | |
| N2 | 47.0 | |
| N3a | 30.4 | |
| N3b | 10.3 | |
| TNM | ||
| I+II | 80.9 | <0.001 |
| III | 31.5 | |
| Tumor location | ||
| L | 59.5 | <0.001 |
| M | 49.3 | |
| U | 37.1 | |
| LM | 37.7 | |
| MU | 28.6 | |
| LMU | 21.4 | |
| Leukocyte | ||
| <6.17 | 55.1 | 0.229 |
| ≥6.17 | 49.5 | |
| Neutrophil | ||
| <3.27 | 56.9 | 0.046 |
| ≥3.27 | 48.4 | |
| Hemoglobin | ||
| <121.2 | 40.0 | <0.001 |
| ≥121.2 | 57.5 | |
| Fibrinogen | ||
| <3.06 | 62.3 | <0.001 |
| ≥3.06 | 42.2 | |
| Prealbumin | ||
| <234.5 | 39.7 | <0.001 |
| ≥234.5 | 64.9 | |
| Albumin | ||
| <42.5 | 46.2 | <0.001 |
| ≥42.5 | 61.4 | |
| Globulin | ||
| <29.9 | 54.1 | 0.170 |
| ≥29.9 | 46.0 | |
| NLR | ||
| <2.2 | 59.1 | 0.006 |
| ≥2.2 | 40.1 | |
| PNI | ||
| <48.73 | 38.1 | <0.001 |
| ≥48.73 | 60.4 | |
| SII | ||
| <527 | 60.0 | <0.001 |
| ≥527 | 38.4 | |
| Total gastrectomy | ||
| Yes | 22.1 | <0.001 |
| No | 61.4 | |
SII: systemic immune-inflammation index; SRCC: signet-ring cell carcinoma; pSRCC: pure signet-ring cell cancer; mSRCC: mixed signet-ring cell cancer; LM: lower and middle; MU: middle and upper; LMU: lower, middle, and upper; PNI: prognostic nutritional index; NLR: lymphocyte to neutrophil ratio.